Lorlatinib in a Child with ALK -Fusion–Positive High-Grade Glioma
- 19 August 2021
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 385 (8) , 761-763
Abstract
Advancements in molecular diagnostics have led to the identification of a new class of pediatric gliomas — infantile hemispheric gliomas — that arise in the cerebral hemispheres and often are histologically confirmed to be malignant (World Health Organization grade III or IV).1,2 These gliomas harbor receptor tyrosine kinase rearrangements in ALK, ROS1, NTRK1/2/3, and MET and are more amenable to therapy, with better survival outcomes, than other pediatric high-grade gliomas.1,2Keywords
Funding Information
- National Cancer Institute (P30CA021765)
- American Lebanese Syrian Associated Charities
This publication has 5 references indexed in Scilit:
- First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung CancerNew England Journal of Medicine, 2020
- Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable OutcomesCancer Discovery, 2020
- Phase I trial of lorlatinib in patients with ALK-driven refractory or relapsed neuroblastoma: A New Approaches to Neuroblastoma Consortium study.Journal of Clinical Oncology, 2020
- Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomasNature Communications, 2019
- High-grade glioma in very young children: a rare and particular patient populationOncotarget, 2017